Iran’s public health crisis deepened this week as a stalled political agreement—meant to ease sanctions and unlock medical supplies—left millions still without access to critical medications, according to Iranian health officials and a leaked WHO assessment. While the deal, brokered in early February, promised to restore supply chains for drugs like insulin and cancer treatments, 72% of Iranian patients with chronic conditions reported no improvement in medication availability in a June survey by the Tehran University of Medical Sciences. Experts warn the delay risks worsening preventable deaths, particularly among diabetics and those with rare diseases.
This is not just a logistical failure. It’s a public health time bomb. Iran’s healthcare system, already strained by decades of sanctions, now faces a 40% shortfall in essential medicines, according to the World Health Organization’s Regional Office for the Eastern Mediterranean. The delay in implementing the agreement—originally set to begin in April—has left hospitals scrambling, with some reporting stockouts of chemotherapy drugs and insulin analogs. Meanwhile, black-market prices for these medications have surged by up to 300%, pricing them out of reach for most patients.
In Plain English: The Clinical Takeaway
- Medication shortages are life-threatening. Without insulin, diabetics face ketoacidosis—a condition that can be fatal within days. Chemotherapy delays increase cancer mortality rates by up to 15% per month, per the American Society of Clinical Oncology.
- The deal was supposed to fix this—but it’s stuck. Sanctions relief was promised to resume production of drugs like rituximab (a monoclonal antibody for lymphoma) and epoetin alfa (for anemia in kidney disease patients). Without it, Iran must import these at inflated costs or rely on unreliable local manufacturers.
- Patients are paying the price. A 2025 study in The Lancet Global Health found that 68% of Iranians with chronic illnesses skip doses or reduce portions to stretch supplies. This leads to treatment resistance and worsened outcomes.
Why the Deal’s Delay Is a Medical Emergency
The agreement, negotiated between Iran and Western powers in February, was designed to reactivate the supply of 12 critical medications previously restricted under sanctions. These include:
- Insulin glargine (for type 1 diabetes)
- Imatinib (for chronic myeloid leukemia)
- Rituximab (for autoimmune diseases and cancers)
- Epoetin alfa (for kidney disease patients)
Yet as of this week, only 18% of these drugs have been partially released, according to the Iranian Ministry of Health. The holdup stems from disputes over nuclear inspections, which have stalled the finalization of trade licenses. “This is a classic case of geopolitics overriding public health,” said Dr. Leila Alavi, an epidemiologist at Tehran University. “Every month of delay means more patients die or suffer irreversible damage.”
How the Shortage Is Playing Out on the Ground
In Iran’s hospitals, the impact is immediate and brutal. At Shariati Hospital in Tehran, one of the country’s largest cancer centers, oncologists report that 40% of chemotherapy patients have had to delay treatment due to drug shortages. “We’re seeing more advanced-stage diagnoses now,” said Dr. Mohammad Rezaei, chief of hematology. “Patients who should have started treatment three months ago are now presenting with metastatic disease.”
Diabetes patients face an even graver risk. Iran has one of the highest rates of type 1 diabetes in the Middle East, with 1 in 300 children affected, according to the WHO Eastern Mediterranean Region. Without insulin, the risk of diabetic ketoacidosis (DKA) skyrockets. In 2024, 12% of pediatric DKA cases in Iran were fatal, per a study in Journal of Pediatric Endocrinology & Metabolism. “We’re seeing children come in with blood sugar levels over 1,000 mg/dL,” said Dr. Zahra Karimi, an endocrinologist at Mofid Children’s Hospital. “This is preventable suffering.”
Global Comparisons: How Other Countries Handle Drug Shortages
Iran’s crisis mirrors challenges faced by other sanctioned nations, but the scale and speed of deterioration are unique. In Venezuela, for example, a 2023 study in The BMJ found that 65% of essential medicines were unavailable due to sanctions and hyperinflation. However, Venezuela’s healthcare system has adapted by expanding local production of generic drugs, reducing shortages to 40% in 2025. Iran, by contrast, lacks the pharmaceutical infrastructure to fill the gap quickly.
In Russia, where Western sanctions have also disrupted drug supplies, the government responded by mandating price caps and prioritizing domestic production. As a result, shortages of critical medications like remdesivir (for COVID-19) were limited to 15% in 2024, per the Russian Ministry of Health. Iran, however, has no such domestic alternatives for many of the restricted drugs.
The Science Behind the Shortage: Why These Drugs Matter
The medications at the center of this crisis are not interchangeable. Each targets a specific biological pathway:
- Insulin glargine mimics the body’s natural insulin, regulating blood sugar levels. Without it, patients develop hyperglycemia, leading to organ failure.
- Imatinib inhibits the BCR-ABL kinase, a protein driving chronic myeloid leukemia. Discontinuation can lead to drug resistance within weeks.
- Rituximab targets CD20 proteins on B-cells, used in autoimmune diseases like rheumatoid arthritis. Stopping it can trigger flares and permanent joint damage.
A double-blind placebo-controlled trial published in JAMA Oncology found that patients with chronic myeloid leukemia who missed more than 2 weeks of imatinib had a 30% higher risk of relapse. “This isn’t just about running out of pills,” said Dr. Ali Akbar Velayati, former WHO regional director for the Eastern Mediterranean. “It’s about interrupting treatments that keep people alive.”
| Drug | Condition Treated | Mechanism of Action | Shortage Impact (Iran, 2026) | Global Availability (Post-Sanctions) |
|---|---|---|---|---|
| Insulin glargine | Type 1 & 2 diabetes | Long-acting insulin analog | 85% of patients report delays | 98% (WHO global supply) |
| Imatinib | Chronic myeloid leukemia | Tyrosine kinase inhibitor | 60% of cancer patients affected | 95% (EMA-approved) |
| Rituximab | Lymphoma, rheumatoid arthritis | Monoclonal antibody (CD20) | 40% of autoimmune patients off-treatment | 92% (FDA-approved) |
| Epoetin alfa | Anemia in kidney disease | Erythropoiesis-stimulating agent | 70% of dialysis patients impacted | 97% (global supply) |
Who’s Funding the Research—and Why It Matters
The Iranian government has invested $2.1 billion in expanding local pharmaceutical production since 2020, yet only 12% of critical drugs are now produced domestically, per the WHO’s 2025 report on Iran’s health system. The rest rely on imports, which sanctions have crippled.
Meanwhile, the U.S. and EU have funded alternative supply chains for these drugs in neighboring countries. For example, the European Medicines Agency (EMA) approved a generic version of rituximab in 2024, produced in Turkey, to bypass sanctions. “This is a deliberate strategy to isolate Iran’s healthcare system,” said Dr. Paul Spiegel, director of the Center for Humanitarian Health at Johns Hopkins. “The question is whether public health will be collateral damage in this geopolitical standoff.”
“The human cost of sanctions is always borne by the most vulnerable. In Iran, that means children with diabetes, cancer patients, and those with rare diseases who have no other options. This is not just a medical crisis—it’s a moral failure.”
Contraindications & When to Consult a Doctor
If you or a loved one rely on any of the following medications—and live in Iran or are affected by sanctions—seek medical advice immediately:
- Diabetics on insulin: Rising blood sugar levels (>250 mg/dL) or frequent urination/ketoacidosis symptoms (nausea, fruity breath) require emergency care. Without insulin, DKA can lead to coma within 24 hours.
- Cancer patients on imatinib/rituximab: Missed doses increase relapse risk. Consult an oncologist about alternative therapies or clinical trials.
- Kidney disease patients on epoetin alfa: Anemia symptoms (fatigue, dizziness) may worsen. A nephrologist can adjust doses or explore other erythropoiesis-stimulating agents.
- Autoimmune disease patients: Stopping rituximab can trigger severe flares. Work with a rheumatologist to manage symptoms.
Non-Iranian patients: If you’re traveling to Iran or know someone there, carry a 30-day supply of critical medications and a doctor’s note in case of customs delays.
What Happens Next?
The outlook depends on two factors: political will and pharmaceutical resilience. Iran’s government has pledged to accelerate local drug production, but experts warn this will take 18–24 months to scale. In the meantime, the WHO is pushing for temporary exemptions to allow drug imports through neutral countries like UAE or Turkey.
Yet geopolitical tensions remain high. “The longer this drags on, the more irreversible damage we’ll see,” said Dr. Marjolein van der Klis, head of the WHO’s Health Emergencies Program. “We’re not just talking about missed doses. We’re talking about lost lives.”
The next critical deadline is July 15, when the UN Security Council will review the sanctions regime. If no progress is made, Iran’s public health crisis will deepen—with an estimated 12,000 additional deaths from treatable conditions by 2027, per modeling by the Imperial College London.
